A
Ardelyx, Inc. (ARDX)
NGM – Real Time Price. Currency in USD
6.61
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
6.61
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. John Bishop Ph.D. | Chief Technical & Quality Officer |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Patient Officer & Interim Chief Medical Officer |
| Mr. Eric Duane Foster | Chief Commercial Officer |
| Mr. James P. Brady | Chief Human Resources Officer |
| Mr. Joseph Reilly | Senior VP of Finance & Principal Accounting Officer |
| Mr. Michael G. Raab | President, CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 8-K | ardx-20260430.htm |
| 2026-04-30 | 10-Q | ardx-20260331.htm |
| 2026-04-29 | DEF 14A | ny20065368x1_def14a.htm |
| 2026-04-29 | ARS | ny20065368x2_ars.pdf |
| 2026-02-19 | 8-K | ardx-20260219.htm |
| 2026-02-19 | 10-K | ardx-20251231.htm |
| 2026-01-08 | 8-K | ardx-20260108.htm |
| 2025-12-17 | 8-K | ardx-20251217.htm |
| 2025-11-03 | S-8 | d45140ds8.htm |
| 2025-11-03 | S-3ASR | d34492ds3asr.htm |
| Mr. Mike Kelliher | Chief Business Officer |
| Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations |
| Ms. Felecia W. Ettenberg | Chief Legal Officer |
| Ms. Sue Hohenleitner | Chief Financial Officer |